What smart money is saying about Kubota Corporation
1 fund in our archive has pitched Kubota Corporation — most recently Aristotle International Equity in December 2025.
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.
Get an email when a fund writes about it
Position history
Between Q4 2025 and Q2 2026, 1 fund letter reported a position in Kubota Corporation, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q2 2026 | 1 | 0 | 0 | 0 |
| Q4 2025 | 0 | 0 | 0 | 1 |
Fund activity · 1 position
- HoldsHarding Loevner Global EquityJune 2026
Listed in Harding Loevner Global Equity’s reported holdings.
Read the letterKubota Corporation
Fund coverage · 1 thesis
- Aristotle International EquityDecember 2025
Kubota Corporation is a leading tractor and construction machinery maker whose maturing share gains and rising capital intensity led to an exit despite strong positions in key markets.
Read the full thesis
Read every full thesis on Kubota Corporation
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→